Human Papillomavirus Vaccines - Immune Responses

被引：125

作者：

Stanley, Margaret ^{[1
]}

Pinto, Ligia A. ^{[2
]}

Trimble, Connie ^{[3
,4
,5
]}

机构：

[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England

[2] NCI Frederick, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA

[3] Johns Hopkins Univ Hosp, Dept Obstet Gynecol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA

[5] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA

来源：

VACCINE | 2012年 / 30卷

关键词：

HPV; virus like particle; VLP; antibody; B cells; L1; protein; L2; cell mediated immunity; VIRUS-LIKE PARTICLES; HPV VACCINATION PROGRAM; INTRAEPITHELIAL NEOPLASIA; ANTIBODY-RESPONSES; NATURAL-HISTORY; YOUNG-WOMEN; T-CELLS; INFECTION; L1; TYPE-16;

D O I：

10.1016/j.vaccine.2012.04.106

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines are highly effective. The available evidence suggests that neutralising antibody is the mechanism of protection. However, despite the robust humoral response elicited by VLP vaccines, there is no immune correlate, no minimum level of antibody, or any other immune parameter, that predicts protection against infection or disease. The durability of the antibody response and the importance of antibody isotype, affinity and avidity for vaccine effectiveness are discussed. Once infection and disease are established, then cellular immune responses are essential to kill infected cells. These are complex processes and understanding the local mucosal immune response is a prerequisite for the rational design of therapeutic HPV vaccines. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Published by Elsevier Ltd.

引用

收藏

页码：F83 / F87

页数：5

相关论文

共 53 条

[1] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[2] Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study [J].

Brotherton, Julia M. L. ;

Fridman, Masha ;

May, Cathryn L. ;

Chappell, Genevieve ;

Saville, A. Marion ;

Gertig, Dorota M. .

LANCET, 2011, 377 (9783) :2085-2092

[3] The humoral response to Gardasil® over four years as defined by Total IgG and competitive luminex immunoassay [J].

Brown, Darron R. ;

Garland, Suzanne ;

Ferris, Daron G. ;

Joura, Elmar ;

Steben, Marc ;

James, Margaret ;

Radley, David ;

Vuocolo, Scott ;

Garner, Elizabeth I. O. ;

Haupt, Richard M. ;

Bryan, Janine T. .

HUMAN VACCINES, 2011, 7 (02) :230-238

[4] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].

Brown, Darron R. ;

Kjaer, Susanne K. ;

Sigurdsson, Kristjan ;

Iversen, Ole-Erik ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Koutsky, Laura A. ;

Tay, Eng Hseon ;

Garcia, Patricia ;

Ault, Kevin A. ;

Garland, Suzanne M. ;

Leodolter, Sepp ;

Olsson, Sven-Eric ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Paavonen, Jorma ;

Steben, Marc ;

Bosch, F. Xavier ;

Dillner, Joakim ;

Joura, Elmar A. ;

Kurman, Robert J. ;

Majewski, Slawomir ;

Munoz, Nubia ;

Myers, Evan R. ;

Villa, Luisa L. ;

Taddeo, Frank J. ;

Roberts, Christine ;

Tadesse, Amha ;

Bryan, Janine ;

Lupinacci, Lisa C. ;

Giacoletti, Katherine E. D. ;

Sings, Heather L. ;

James, Margaret ;

Hesley, Teresa M. ;

Barra, Eliav .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935

[5] Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lmphoid tissues [J].

Campbell, DJ ;

Butcher, EC .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (01) :135-141

[6] The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women [J].

Carter, JJ ;

Koutsky, LA ;

Wipf, GC ;

Christensen, ND ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :927-936

[7] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].

Carter, JJ ;

Koutsky, LA ;

Hughes, JP ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919

[8] Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera [J].

Carter, Joseph J. ;

Wipf, Greg C. ;

Madeleine, Margaret M. ;

Schwartz, Stephen M. ;

Koutsky, Laura A. ;

Galloway, Denise A. .

JOURNAL OF VIROLOGY, 2006, 80 (10) :4664-4672

[9] Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies [J].

Christensen, ND ;

Dillner, J ;

Eklund, C ;

Carter, JJ ;

Wipf, GC ;

Reed, CA ;

Cladel, NM ;

Galloway, DA .

VIROLOGY, 1996, 223 (01) :174-184

[10] Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia [J].

Daayana, S. ;

Elkord, E. ;

Winters, U. ;

Pawlita, M. ;

Roden, R. ;

Stern, P. L. ;

Kitchener, H. C. .

BRITISH JOURNAL OF CANCER, 2010, 102 (07) :1129-1136

← 1 2 3 4 5 6 →